Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Genetic basis found for the perseverance of bowel cancer

04 March 2013

By Reuben Harwood

Appeared in BioNews 695

Losing genes that help stabilise a cell's DNA may explain why some cancers are resistant to treatment, say scientists. Bowel cancer cells that lost one of three genes displayed unstable chromosomes; a trait that leads to different chromosome numbers within tumour cells and is linked to poor prognosis in patients.

Professor Charles Swanton, who led the study at the Cancer Research UK London Research Institute and University College London Cancer Institute said '... cancers are able to continually shuffle their genetic pack, and deal themselves a better 'genetic hand'. This diversity may help them adapt to new environments, promote tumour spread, or contribute to cancer drug resistance'.

Professor Swanton's team found three genes, previously not known to have a role in maintaining chromosome stability, were crucial for cells to correctly copy their chromosomes during cell division. These genes, located on chromosome region 18q, were often lost in bowel cancer cells. This resulted in abnormally shaped chromosomes, variable numbers of chromosomes and DNA stress.

The researchers showed they could improve the genetic stability of bowel cancer cells lacking these genes by supplying them with an excess of nucleosides, the 'raw materials' needed to build DNA. Cancer cells rapidly divide and make copies of their DNA. An insufficient supply of nucleosides during this process results in DNA errors, which can be beneficial to a tumour.

'By unravelling how this process happens we can now look at turning this strength of cancers into a weakness – too much instability prevents cancer cells from being able to function and ultimately stopping them from working normally, causing them to die. We're now looking for ways in which this process can be targeted in order to tip cancer cells over the edge', said Professor Swanton.

Cancer Research UK chief scientist, Professor Nic Jones, noted that the chromosome region where the three genes in question are found 'is lost in many cancers'. The study's findings may therefore be relevant not only to bowel cancer, but other types of cancer as well.

The study was published in the journal Nature.

SOURCES & REFERENCES
Cancer Research UK (press release) | 27 February 2013
 
Nature | 27 February 2013
 
BBC News | 28 February 2013
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

25 January 2016 - by Hannah Somers 
Scientists in the USA have identified a biomarker that could predict which patients with colon cancer might benefit from chemotherapy to prevent recurrences of the disease after surgical treatment....
06 May 2014 - by James Brooks 
A genetic variant carried by one in three people raises the risk of bowel cancer for people who eat a lot of processed meat, a study has found...
08 April 2013 - by Siobhan Chan 
The largest ever study into cancer genes has identified more than 80 genetic markers for breast, prostate and ovarian cancer....

07 January 2013 - by Chris Baldacci 
Two rare genetic mutations have been linked to a higher risk of developing bowel cancer...
13 August 2012 - by Cait McDonagh 
A faulty gene linked to bowel cancer interacts with dietary iron to significantly increase the risk of developing the disease, research on mice suggests...
30 July 2012 - by Dr Zara Mahmoud 
Some cases of glioblastoma - a particularly aggressive form of brain cancer - may be due a genetic mutation where two separate genes fuse into one, scientists report...
12 March 2012 - by Maren Urner 
A single tumour can have many different genetic mutations at various locations, cancer researchers have found. In a study, two thirds of the specific genetic faults identified in tumours were not repeated in the same tumour...
08 March 2010 - by Dr Sophie Pryor 
Scientists have developed a way to identify six key genes which, if faulty, can prevent particular chemotherapy drugs from working in patients with breast cancer. The findings bring cancer therapy one step closer to the promise of targeted treatments for patients, based on the genetic characteristics of their tumours....

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation